If youâre want a strong portfolio, then having a few blue chips in there could give you a great foundation to build from.
But which blue chip ASX 200 shares could be in the buy zone? Here are three from different sides of the market to consider:
Goodman Group (ASX: GMG)
The first blue chip ASX 200 share that could be a buy is Goodman Group. It is a leading integrated commercial and industrial property company. Thanks to its successful strategy of developing high quality industrial properties in strategic locations, Goodman has been a standout performer over the last decade. The good news is that it has been tipped to continue its growth in the future.
Citi is a fan and has a buy rating and $21.10 price target on its shares. Its analysts continue to “favour industrial exposure, and remain attracted to GMGâs best-in-class balance sheet.”
Cochlear Limited (ASX: COH)
Another ASX 200 share that could be a buy is Cochlear. It is one of the worldâs leading hearing solutions companies. Thanks to its portfolio of world class products, which have been developed through its significant annual investment in research and development, Cochlear appears well-placed for long term growth. Particularly given its strong position in a market benefiting from ageing populations.
Morgans is bullish on Cochlear and has an add rating and $236.70 price target on its shares. It believes the Nucleus 8 launch will be a key driver of near term growth.
Rio Tinto Limited (ASX: RIO)
A final ASX 200 blue chip share that has been rated as a buy is Rio Tinto. It is of course one of the world’s largest miners and the owner of a collection of world class operations across different commodities and geographies.
Goldman Sachs is positive on the miner due to its âcompelling valuation” and production growth expectations. Goldman currently has a buy rating and $132.00 price target on Rio Tinto’s shares.
The post Why experts say these ASX 200 blue chip shares are buys appeared first on The Motley Fool Australia.
FREE Guide for New Investors
Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…
For over a decade, we’ve been helping everyday Aussies get started on their journey.
And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.
Yes, Claim my FREE copy!
*Returns as of February 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Here’s the iron ore price forecast for 2023: CBA
- Own Rio Tinto shares? Here’s what the market is expecting from its FY 2022 results
- This ASX 200 share is one of my top ideas to rake it in on a recovery
- How I’d generate a $50,000 retirement income from Rio Tinto shares
- Buy and hold these ASX 200 shares: experts
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/dPgZR4M